Singapore-based biotech startup Anomaly Bio has raised US$2.6 million (S$3.37 million) in a pre-seed funding round led by San Francisco–based Pebblebed Ventures.
Other participants in the round include Akshay Kothari (Notion), Sean Hunt (Solugen), Eben Bayer (Ecovative), and Mithun Sacheti (CaratLane), among others.
Across the world, ingredient supply chains are struggling because of political conflicts and environmental problems.
Tariffs, wars, pandemics, and droughts have made once-dependable systems unreliable, causing delays and shortages that now affect everyday essential products.
Cyclones in Madagascar have damaged vanilla crops, and the Russia–Ukraine war has caused shortages of fertilizer and grain. These problems have spread across global markets, leading to record price swings in key commodities like cocoa, palm oil, corn, and sugarcane.
These issues aren’t just random events — they reveal deeper weaknesses in the global supply system.
Anomaly’s solution uses microbes as tiny factories to replace weak and unreliable supply chains with a new kind of manufacturing that can be scaled, produced on demand, and used anywhere in the world.
By engineering microbes to turn sugar into bio-based ingredients, Anomaly hopes to create new opportunities in areas like crop protection, nutrition, personal care, and more.
“As the world’s ingredient landscape transforms, we want to build a global ingredients company from the ground up,” said Armaan. “There is a rare opportunity to stand alongside legacy industry leaders, but powered by synthetic biology and advanced fermentation.”
Anomaly Bio earlier received more than US$120,000 in non-dilutive grants from MIT’s WFA Prize 2025 and the WTFund Fellowship.
The company has also received support from the National University of Singapore (NUS) and Mars Petcare.
Read more- Wonderful raises $100 million Series A round led by Index Ventures
